Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Don Baxter

Ralph Falk

Thomas Stallkamp

Baxter International Inc.

Avanos Medical, Inc., a medical technology company, focuses on delivering medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands. The company also provides a portfolio of non-opioid pain solutions, including acute pain products, such as On-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems; and interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.

Avanos Medical, Inc.

Mapi Pharma is a clinical stage pharmaceutical company that develops complex active pharmaceutical ingredients and proprietary pharmaceuticals, including long acting depot injectable drugs.

Mapi Pharma

Medical Device Manufacturing Centre provides medical device developers and manufacturers with advice, technical expertise, and facilities to translate medical device concepts to commercial products. The MDMC offers services including engineering and manufacturing expertise, business development, clinical and statistical expertise, and regulatory guidance. Self-described as supporting Scottish companies with the transition to small batch commercial prototypes.

Metric
Company Name	Baxter International Inc.	Avanos Medical, Inc.	Mapi Pharma	Medical Device Manufacturing Centre
Symbol	BAX	AVNS
MSH ID	COM:BAXTER	COM:AVANOS	COM:MAPI-PHARMA	UK:AC:MDMC
Market	STOCKS	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare	Healthcare & Health Services	Healthcare & Health Services
Industry	Medical - Instruments & Supplies	Medical - Devices	Pharmaceuticals	Medical Device Manufacturing
Country	US	US	IL	GB
Stage			Corporate Round
Employee Count	60K	3.77K
Website	baxter.com	avanos.com	mapi-pharma.com	mdmc.ac.uk
LinkedIn
Founders

Metric
Market Cap	17.45B	890.08M
Enterprise Value
Monthly Web Traffic			612
Web Traffic Growth
Valuation
Raised Capital			20M

Metric
Revenue	14.81B	673.30M
Revenue (LTM)
Revenue (NTM)
Gross Profit	4.97B	382.70M
EBITDA	1.75B	98.50M
Operating Income	390M	52.40M
Net Income	2.66B	-61.80M
EPS	5.25	-1.33
Diluted EPS	5.25	-1.33
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.36	0.57
Operating Profit Margin	0.06	0.07
EBITDA Margin	0.12	0.15
Net Profit Margin	0.18	0.02
Return on Equity	0.38	0.01
Return on Assets	0.10	0.01
Return on Capital Employed	0.05	0.03

COM:BAXTER

Baxter International Inc

Last Close

32.99

22/11 21:00

Market Cap

17.45B

Beta: -

Volume Today

4.65M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	7.55	-15.55
P/B Ratio	2.41	0.71
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	1.42	1.66
EV Multiple	8.56	13.78

Metric
Days Sales Outstanding	61.33	70.67
Days Payables Outstanding	45.88	56.73
Days Inventory Outstanding	113.15	205.17
Operating Cycle	178.17	275.64
Cash Conversion Cycle	130.96	205.02
Asset Turnover	0.57	0.42

Metric
Operating Cash Flow	1.73B	32.40M
Free Cash Flow	1.03B	14.60M
Cash Flow to Debt	0.12	0.33
Operating Cash Flow/Sales	0.12	0.09
Free Cash Flow Yield	0.05	0.04

Metric
Cash & Equivalents	3.19B	87.70M
Accounts Receivable	-66M	39M
Inventory	2.82B	163.20M
Goodwill	6.51B	796.10M
Debt to Capitalization	0.64	0.15
Debt to Assets	0.55	0.18
Current Ratio	1.94	3.07
Quick Ratio	1.01	1.49

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.01	0.02
R&D to Revenue	0.04	0.04
SG&A to Revenue	0.06